HealthTree Logo
search more_vert
close
person Sign In / Create Account
What are the different MDS types?
Posted: Aug 22, 2023
What are the different MDS types?  image

Myelodysplastic syndromes are a group of blood disorders that affect how bone marrow makes blood cells. MDS can lead to low blood cell counts (cytopenia), and the cells in bone marrow not developing properly (dysplasia). MDS can also increase the risk of developing acute myeloid leukemia (AML) later on.

In 2022, the World Health Organization (WHO) updated the classification of MDS to better understand the disease.

MDS with defining genetic abnormalities:

  • MDS with low blasts and isolated 5q deletion (MDS-5q)
  • MDS with low blasts and SF3B1 mutation (MDS- SF3B1)
  • MDS with biallelic TP53 inactivation (MDS-bi TP53)

MDS, morphologically defined (structural abnormalities in the cells): 

  • MDS with low blasts (MDS-LB)
  • MDS, hypoplastic (MDS-h)
  • MDS with increased blasts (MDS-IB), MDS-IB1, MDS-IB2
  • MDS with fibrosis (MDS-f)

Childhood MDS:

  • Childhood MDS with low blasts (hypocelular and not otherwise specified)
  • Childhood MDS with increased blasts


The WHO classification system of MDS is based on clinical features, peripheral blood, bone marrow findings, and cytogenetic analysis. This classification of myeloid neoplasms also includes another diverse mix of neoplasms that share some features with myelodysplastic syndromes and can be treated similarly.  
Chronic myelomonocytic leukemia (CMML)

  • Myelodysplastic/myeloproliferative neoplasm with neutrophilia
  • Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis 
  • Myelodysplastic/myeloproliferative neoplasm, not otherwise specified

The WHO classification system helps healthcare professionals to provide more accurate diagnoses and implement personalized treatment strategies. Collaborative efforts between researchers, clinicians, and patients will further our understanding of these disorders and drive progress toward improved treatment options and, ultimately, better outcomes for those affected by Myelodysplastic Syndromes.

Reference: 
https://emedicine.medscape.com/article/2007806-overview?form=fpf
 

The author Jimena Vicencio

about the author
Jimena Vicencio

Jimena is an International Medical Graduate who is part of the HealthTree Patient Experience team. She loves learning new things led by her curiosity, playing with her pets, and exercising in her free time.

Get the latest thought leadership on Myelodysplastic Syndromes delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myelodysplastic Syndromes Newsletter" for Myelodysplastic Syndromes news, life with Myelodysplastic Syndromes stories, Myelodysplastic Syndromes clinical trials, Myelodysplastic Syndromes 101 articles and events with Myelodysplastic Syndromes experts.

Thanks to our HealthTree Community for Myelodysplastic Syndromes Sponsors:

AbbVie
Bristol Myers Squibb

Follow Us

facebook twitter